[1] TRIEBEL F,JITSUKAWA S,BAIXERAS E,et al.LAG-3,a novel lymphocyte activation gene closely related to CD4[J]. J Exp Med,1990,171(5):1393-1405.
[2] DENG W W,MAO L,YU G T,et al.LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma[J]. Oncoimmunology,2016,5(11):e1239005.
[3] YANG J,WANG H,WANG M,et al.Involvement of LSECtin in the hepatic natural killer cell response[J]. Biochem Biophys Res Commun,2016,476(1):49-55.
[4] WOO S R,LI N,BRUNO T C,et al.Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4[J]. Eur J Immunol,2010,40(6):1768-1777.
[5] ANDERSON A C,JOLLER N,KUCHROO V K.Lag-3,Tim-3,and TIGIT:Co-inhibitory receptors with specialized functions in immune regulation[J]. Immunity,2016,44(5):989-1004.
[6] GOLDBERG M V,DRAKE C G.LAG-3 in cancer immunotherapy[J]. Curr Top Microbiol Immunol,2011,344:269-278.
[7] 曲通,周雪萌,刘海石,等.免疫检查点抑制剂在恶性淋巴瘤中的应用研究进展[J]. 中国肿瘤临床,2016,43(20):922-926.
[8] PREVITE D M,MARTINS C P,O'CONNOR E C,et al.Lymphocyte activation gene-3 maintains mitochondrial and metabolic quiescence in naive CD4+ T cells[J]. Cell Rep,2019,27(1):129-141.
[9] COOK K D,WHITMIRE J K.LAG-3 confers a competitive disadvantage upon antiviral CD8+ T cell responses[J]. J Immunol,2016,197(1):119-127.
[10] GANDHI M K,LAMBLEY E,DURAISWAMY J,et al.Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients[J]. Blood,2006,108:2280-2289.
[11] WOO S R,TURNIS M E,GOLDBERG M V,et al.Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape[J]. Cancer Res,2012,72(4):917-927.
[12] SEGA E I,LEVESON-GOWER D B,FLOREK M,et al.Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation[J]. PLoS One,2014,9(1):e86551.
[13] ANVARI S,GRIMBERGEN A,DAVIS C M,et al.Protein transport inhibitors downregulate the expression of LAG-3 on regulatory T cells[J]. J Immunol Methods,2017,447:47-51.
[14] WORKMAN C J,WANG Y,EL KASMI K C,et al.LAG-3 regulates plasmacytoid dendritic cell homeostasis[J]. J Immunol,2009,182(4):1885-1891.
[15] CASTELLI C,TRIEBEL F,RIVOLTINI L,et al.Lymphocyte activation gene-3 (LAG-3,CD223) in plasmacytoid dendritic cells (pDCs):a molecular target for the restoration of active antitumor immunity[J]. Oncoimmunology,2014,3(11):e967146.
[16] WAUGH K A,LEACH S M,MOORE B L,et al.Molecular profile of tumor-specific CD8+ T cell hypofunction in a transplantable murine cancer model[J]. J Immunol,2016,197(4):1477-1488.
[17] AROLT C,MEYER M,RUESSELER V,et al.Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas[J]. Cancer Immunol Immunother,2020,69(7):1363-1373.
[18] BAITSCH L,BAUMGAERTNER P,DEVêVRE E,et al.Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients[J]. J Clin Invest,2011,121(6):2350-2360.
[19] KLEIN S,MAUCH C,WAGENER-RYCZEK S,et al.Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy[J]. Cancer Immunol Immunother,2019,68(6):973-982.
[20] PIGNON J C,JEGEDE O,SHUKLA S A,et al.irRECIST for the evaluation of candidate biomarkers of response to nivolumab in metastatic clear cell renal cell carcinoma:analysis of a phase Ⅱ prospective clinical trial[J]. Clin Cancer Res,2019,25(7):2174-2184.
[21] XIA L,LIU Y,WANG Y.PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer:current status and future directions[J]. Oncologist,2019,24(Suppl 1):S31-S41.
[22] LARKINS E,BLUMENTHAL G M,YUAN W,et al.FDA approval summary:pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy[J]. Oncologist,2017,22(7):873-878.
[23] GIULIA M,FRAGOMENI S M,INZANI F,et al.Molecular pathways in vulvar squamous cell carcinoma:implications for target therapeutic strategies[J]. J Cancer Res Clin Oncol,2020,146(7):1647-1658.
[24] MATSUZAKI J,GNJATIC S,MHAWECH-FAUCEGLIA P,et al.Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer[J]. Proc Natl Acad Sci U S A,2010,107(17):7875-7880.
[25] GANDHI M K,LAMBLEY E,DURAISWAMY J,et al.Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients[J]. Blood,2006,108(7):2280-2289.
[26] HUANG R Y,EPPOLITO C,LELE S,et al.LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model[J]. Oncotarget,2015,6(29):27359-27377.
[27] OKAZAKI T,OKAZAKI I M,WANG J,et al.PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice[J]. J Exp Med,2011,208(2):395-407.
[28] WIERZ M,PIERSON S,GUYONNET L,et al.Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia[J]. Blood,2018,131(14):1617-1621.
[29] HUANG R Y,FRANCOIS A,MCGRAY A R,et al.Compensatory upregulation of PD-1,LAG-3,and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer[J]. Oncoimmunology,2017,6(1):e1249561.
[30] GHOSH S,SHARMA G,TRAVERS J,et al.TSR-033,a novel therapeutic antibody targeting LAG-3,enhances T-cell function and the activity of PD-1 blockade in vitro and in vivo[J]. Mol Cancer Ther,2019,18(3):632-641.
[31] ZELBA H,BEDKE J,HENNENLOTTER J,et al.PD-1 and LAG-3 dominate checkpoint receptor-mediated T-cell inhibition in renal cell carcinoma[J]. Cancer Immunol Res,2019,7(11):1891-1899.
[32] WALKER L S,SANSOM D M.Confusing signals:recent progress in CTLA-4 biology[J]. Trends Immunol,2015,36(2):63-70.
[33] VAN COILLIE S,WIERNICKI B,XU J.Molecular and cellular functions of CTLA-4[J]. Adv Exp Med Biol,2020,1248:7-32.
[34] O'NEILL R E,CAO X.Co-stimulatory and co-inhibitory pathways in cancer immunotherapy[J]. Adv Cancer Res,2019,143:145-194.
[35] ZHANG W,SHI L,ZHAO Z,et al.Disruption of CTLA-4 expression on peripheral blood CD8+ T cell enhances anti-tumor efficacy in bladder cancer[J]. Cancer Chemother Pharmacol,2019,83(5):911-920.
[36] WEI S C,ANANG N A S,SHARMA R,et al.Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies[J]. Proc Natl Acad Sci U S A,2019,116(45):22699-22709.
[37] 刘昊,李新颖,罗龙龙,等.淋巴细胞活化基因3分子生物学功能及其抗体药物临床应用研究进展[J]. 中国药理学与毒理学杂志,2019,33(1):70-78.
[38] KRAMAN M,FAROUDI M,ALLEN N L,et al.FS118,a bispecific antibody targeting LAG-3 and PD-L1,enhances T-Cell activation resulting in potent antitumor activity[J]. Clin Cancer Res,2020,26(13):3333-3344.
[39] BUROVA E,HERMANN A,DAI J,et al.Preclinical development of the anti-LAG-3 antibody REGN3767:characterization and activity in combination with the anti-PD-1 antibody cemiplimab in human PD-1xLAG-3-knockin mice[J]. Mol Cancer Ther,2019,18(11):2051-2062.
[40] BRIGNONE C,GUTIERREZ M,MEFTI F,et al.First-line chemoimmunotherapy in metastatic breast carcinoma:combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity[J]. J Transl Med,2010,8:71.
[41] GIULIA M,FRAGOMENI S M,INZANI F,et al.Molecular pathways in vulvar squamous cell carcinoma:implications for target therapeutic strategies[J]. J Cancer Res Clin Oncol,2020,146(7):1647-1658.
[42] ANGIN M,BRIGNONE C,TRIEBEL F.A LAG-3-specific agonist antibody for the treatment of T Cell-hnduced autoimmune diseases[J]. J Immunol,2020,204(4):810-818.
[43] ANDREWS L P,MARCISCANO A E,DRAKE C G,et al.LAG3 (CD223) as a cancer immunotherapy target[J]. Immunol Rev,2017,276(1):80-96.
[44] WASHBURN M L,WANG Z,WALTON A H,et al.T cell-and monocyte-specific RNA-sequencing analysis in septic and nonseptic critically ill patients and in patients with cancer[J]. J Immunol,2019,203(7):1897-1908.
[45] DONG Y,LI X,ZHANG L,et al.CD4(+) T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B[J]. BMC Immunol,2019,20(1):27.
[46] ANGELOPOULOU E,PAUDEL Y N,VILLA C,et al.Lymphocyte-activation gene 3 (LAG3) protein as a possible therapeutic target for parkinson's disease:molecular mechanisms connecting neuroinflammation to α-synuclein spreading pathology[J]. Biology,2020,9(4):86. |
